Supernus Pharmaceuticals, Inc. SUPN

What this company does

Supernus Pharmaceuticals develops and commercializes prescription products for the treatment of central nervous system diseases. Its marketed portfolio includes approved treatments for attention-deficit hyperactivity disorder, dyskinesia in Parkinson's Disease patients receiving levodopa-based therapy, hypomobility in Parkinson's Disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. As of December 31, 2025 it employed 778 full-time employees in the United States. The company's principal executive offices are located in Rockville, Maryland. It markets its key products through its own sales forces in the U.S. and enters into collaborations with other pharmaceutical companies to commercialize them outside the U.S. Each of its three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 15% of total product revenue, and together they accounted for more than 76%. All manufacturing operations, covering the production of raw materials, dosage form product and product packaging, are carried out by third-party contract manufacturing organizations. The company was incorporated in Delaware, commenced operations in 2005, became publicly traded in 2012, and is listed on the NASDAQ Stock Exchange under the ticker symbol SUPN.

Written from the business description in SUPERNUS PHARMACEUTICALS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.